Answers are grounded in this paper and cite their sources.
Sir, Adequate therapy of herpes simplex virus (HSV) encephalitis relies upon good central nervous system (CNS) delivery of aciclovir and adequate duration of treatment as shorter courses of treatment have been associated with relapse of disease.1 The current paediatric practise is to treat with 3 weeks of intravenous (iv) aciclovir at 1500 mg/m2/day. Despite this, relapses have been reported that may represent either frank viral relapse or a post-infectious movement disorder.2 Long-term oral aciclovir therapy like that used in neonatal HSV-2 disease3 may benefit children with HSV-1 encephalitis. Valaciclovir is rapidly metabolized to aciclovir producing plasma concentrations three to five times higher than oral aciclovir4 and may thus provide a better alternative to oral aciclovir. Its use in children in a variety of herpes virus infections has been reviewed,4,5 but is confined mainly to non-CNS disease.6,7 Here, we report our experience in the therapeutic monitoring of plasma and cerebral spinal fluid (CSF) aciclovir concentrations in five children. Three very young children aged 20 months (patient 1), 11 months (patient 2) and 6 months (patient 3) with relapsing HSV-1 encephalitis were treated with long-term oral valaciclovir after completing a course of iv aciclovir at relapse. Two children (patients 4 and 5) with suspected viral encephalitis were treated with iv aciclovir. CSF aciclovir concentrations were only measured when a lumbar puncture was clinically indicated. Parental consent was obtained for the procedures and long-term oral valaciclovir therapy.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: